ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

What Rheumatologists Should Know About B Cell Tolerance & Autoimmunity

Katie Robinson  |  Issue: October 2025  |  October 8, 2025

“Clonal redemption provides a mechanism for these anergic B cells to be safely recruited into protective immune responses,” they add.

Neoantigens & Autoimmunity 

Autoimmunity can result when the immune system encounters previously hidden, or absent, antigens or those that are modified versions of self-proteins. Breaks in B cell tolerance may be triggered by several factors, such as a genetic predisposition toward B cell activation, T cell tolerance defects or the emergence of neoantigens.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Neoantigens can initiate breaks in B cell tolerance, as demonstrated in the case presentation of Alport syndrome, which is caused by mutations in genes encoding subunits of type IV collagen proteins. The kidney allograft introduced the patient to previously absent collagen IV antigens, triggering an alloimmune response. This led to the development of de novo anti-GBM disease targeting the kidney allograft. 

“The notion that neoantigens can initiate breaks in immune tolerance applies to various autoimmune diseases. For example, post-translational modifications of self-proteins can create novel epitopes recognized as foreign by the immune system. A classic example is the citrullination of proteins in rheumatoid arthritis, leading to the production of anti-citrullinated protein antibodies that drive inflammation and joint damage,” the authors write. 

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Additional mechanisms for B cell tolerance breaks through the formation of neoantigens include molecular mimicry, in which pathogen-associated foreign antigens have a similar structure or sequence to self-antigens. An example of this is Guillain-Barré syndrome, in which Campylobacter jejuni antigens resemble nerve gangliosides. Cancer neoantigens can also initiate breaks in B cell tolerance, such as with POLR3A mutations in paraneoplastic scleroderma.

“Understanding the mechanisms shaping the B cell repertoire and governing the maintenance of B cell tolerance is paramount for developing effective strategies to prevent and treat humoral auto­immunity,” Dr. Jackson and Dr. Ponnan conclude.


Katie Robinson is a medical writer in New York.

References

  1. Bucala R, Solomon DH. Immunology for the rheumatologist: Arthritis & Rheumatology introduces a new problem-based immunology review series with great educational potential. Arthritis Rheumatol. 2024 Jan;76(1):9–10.
  2. Ponnan SM, Jackson SW. Mechanisms of B cell tolerance in health and autoimmunity. Arthritis Rheumatol. 2025 July 10. Epub ahead of print.

Disclosures 

Dr. Jackson is a current or previous consultant for Amgen, Merck, IgM BioSciences, Sail BioMedicines, Bristol-Myers Squib, Variant Bio and ChemoCentryx Inc.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsOther Rheumatic ConditionsResearch Rheum Tagged with:Alport syndromeanti-GBM diseaseautoantibodiesautoreactive B cellsB cell toleranceB cellsGlomerulonephritiskidney diseaseneoantigensT-cells

Related Articles

    Is B a Key to Autoimmune Therapy?: B Cell-Targeted Therapies in Autoimmune Disease

    January 1, 2010

    A perspective on B cell–targeted therapies in autoimmune disease

    Cellular Therapy of Autoimmune Disease

    November 1, 2008

    Is a novel treatment breakthrough on the horizon?

    How a Nuclear Molecule Alarms the Immune System

    August 1, 2011

    The role of HMGB1 in the pathogenesis of lupus nephritis

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences